The analysis evaluates UnitedHealth (UNH) using forward price-to-earnings ratios from Fiscal AI and a proprietary discounted cash flow model. It notes UNH's forward P/E of 22 and increase from lows of 14-13 earlier in the year. The DCF model suggests an intrinsic value of $449.17 per share, compared to a current market price of $358.77. The analyst believes the company undervalued, taking into account consistent free cash flow and customer base. The underperformance in 2025 is attributed to a company's misjudgment in estimates for how much it will cost to serve their customers, something correctable by adjusting the pricing policy. The last evaluation, on September 23rd, rated UNH as a buy, risk/reward remain attractive. The analyst acknowledges a business trading at a lower price will provide better opportunity, noting when it was trading at 275/250 or even 285. The analyst considers this a buy, rating to be confirmed.